Junion

Established in 2021 and based in Xiamen, China, Junion operates as an innovative therapies developer that mainly provides innovative treatments for chronic diseases throughout their entire life cycle. It has R&D centers and production bases in Singapore and Xiamen. The company has obtained more than 20 patents. In April 2025, Junion raised approximately CNY 100 million in series A funding co-led by new investors Zhangzhou State Owned Capital Operation Group and Xiamen Guoxing Investment.

The company focuses on the development of innovative treatments for chronic diseases throughout the entire cycle, and uses materials science, pharmacy, biology, machine learning, and other disciplines and technologies to develop drug-device combination products. Products include gastric volume weight loss capsules (JTX-102) and risperidone oral delivery systems. JTX-102 is an oral device used to help overweight or obese adults treat obesity symptoms or manage their weight. Products focus on chronic diseases such as mental illness, obesity, diabetes, and metabolic-related fatty liver.

The company generates revenue by providing drug-device combination products and innovative treatments for chronic diseases. The company will use the series A funding for the registration, production, and sales of the first oral weight loss device, and to accelerate the product pipeline development process of multiple core innovative drug-device combination technology platforms.